SanFran, from my perspective if the zen3694 trial has a significant positive impact on metastatic castration resistant prostrate cancer from my perspective, even though the results do not directly relate to CVD, diabetes, etc I believe that positive results will provide a strong underpinning and belief in the epigenetic knowledge bank built by Resverlogix and translated to Zenith.

That type of result will give increased credibility to their advanced science and 8 year lead in this epigenetic field of BET inhibition. RVX research is already being accepted in prestigious, peer reviewed journals. Even some positive impact on prostate cancer with these very ill patients will cause the scientific and investment communities to take notice.

So positive results on prostate combined with all of the very positive post hoc analysis of apabetalone (rvx-208) IMHO should result in a huge credibility boost to RVX.

So then the question is how Don will perform on the business side?

Toinv